hiv-1

Documents about hiv-1

• Diarylaniline Derivatives as a Distinct Class of HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors#7902HAL (France)
• Effect of TAR hairpin stabilization on HIV-1 reverse transcription.#209521NCBI PubMed Central
• A Phase 1 Trial to Evaluate CAP256V2LS in Healthy Adults#303592ClinicalTrials.gov
• Machine Learning Identifies Potential Accessory Resistance-Associated Mutations in HIV-1 Integrase#374181Europe PMC
• HIV-1 Peptide Immunisation of Individuals in West Africa to Prevent Disease#471497ClinicalTrials.gov
• Investigating The Hiv-1 Antiviral Activity Of Crispr-Mediated Slfn11 And Cdkn1a Upregulation#990417USM Repository
• A Study to Evaluate Efficacy, Safety and Tolerability in Antiretroviral Therapy (ART)-Experienced Participants of at Least 50 Years of Age Living With Human Immunodeficiency Virus (HIV) With Virologic Suppression Who Switch to DTG/3TC FDC From BIC/FTC/TAF#874737ClinicalTrials.gov
• Factors influencing antiretroviral therapy switching in people with virologically suppressed HIV-1: a cross-sectional multicenter study in France#261991HAL (France)
• Rôle de l’héparanase-1 dans les infections par le VIH-1 et le VHB : évaluation de l’inhibiteur PI-88 comme antiviral à large spectre#665309HAL (France)
• A Study to Evaluate the Efficacy, Safety, and Tolerability of Using an Oral Once-daily 2 Drug Regimen Compared to an Oral Once-daily 3 Drug Regimen for the Treatment of Human Immunodeficiency Virus (HIV)-1 in Adults Who Have Not Previously Taken Antiretroviral Therapy#253159ClinicalTrials.gov
• Central memory CD4+ T cells are preferential targets of double infection by HIV-1 Retroviruses#220231UNSWorks Repository
• Evaluating the Safety and Efficacy of the VRC01 Antibody in Reducing Acquisition of HIV-1 Infection Among Men and Transgender Persons Who Have Sex With Men#208256ClinicalTrials.gov
• Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant HIV-1 Envelope Protein SOSIP v8.2 763 Vaccine, Adjuvanted With MPLA Liposomes, in Healthy, HIV-Uninfected Adults#471484ClinicalTrials.gov
• A Phase IV, Open-label Single-arm Study Investigating the Pharmacokinetics and Pharmacodynamics of the Antiretroviral Combination of Rilpivirine and Ritonavirboosted Darunavir in Therapy-naive HIV-1 Infected Patients.#879635ClinicalTrials.gov
• HIV GP120 protein increases the function of connexin 43 hemichannels and pannexin-1 channels in astrocytes: Repercussions on astroglial function#948285Repositorio de Universidad Autónoma de Chile.
• Depletion of Serum Amyloid P Component to Enhance the Immune Response to DNA Vaccination#966781ClinicalTrials.gov
• microRNA-422a promotes HIV replication and innate immune evasion by targeting MECP2#609464eScholarship
• Multicentre Study To Assess Changes In Bone Mineral Density Of The Switch From Protease Inhibitors To Dolutegravir In HIV-1-Infected Subjects With Low Bone Mineral Density#868627ClinicalTrials.gov
• The OPENS Trial: Offering Women PrEP (Aim 1)#913301ClinicalTrials.gov
• Multidisciplinary studies with mutated HIV-1 capsid proteins reveal structural mechanisms of lattice stabilization#240362Ora Oxford University Research
• Genotypic challenges in implementing broadly neutralizing antibody-based long-acting HIV-1 therapies.#244237NCBI PubMed Central
• Generation of human TRIM5alpha mutants with high HIV-1 restriction activity#402095DataCite
• The MISTRAL Study: Gut Microbiome Correlates of Serious AIDS and Non-AIDS Events#411232ClinicalTrials.gov
• HIV-1 Integration Favors Genes Associated With Promoter-Proximal Pol II Pausing#643846Harvard DASH
• Abacavir, Dolutegravir and Lamivudine Dispersible Tablets (60 mg/5 mg/30 mg)#897187ClinicalTrials.gov
• Viral and Antiretroviral Dynamics in HIV-1 Mother-to-Child Transmission Fluids#918607ClinicalTrials.gov
• HIV-V3Augur: A Novel Machine Learning Model for Predicting HIV-1 Tropism in Sub-Subtype A6 and CRF63_02A6, Predominant Variants in Russia and Countries of the Former Soviet Union.#427997NCBI PubMed Central
• From giant components to communities: community-level insights for prioritizing interventions within large clusters of HIV-1 transmission networks#642255Europe PMC
• Comparison of Two Combinations in Antiretroviral Post-Exposure Prophylaxis for HIV-1: Tenofovir/Emtricitabine (Truvada ®) + Lopinavir/Ritonavir (Kaletra ®) vs Tenofovir/Emtricitabine/Cobicistat/Elvitegravir (Stribild ®). Prospective, Randomized, Open.#833714ClinicalTrials.gov
• A Comparison of the Effectiveness, Safety, and Tolerability of Two Different Hepatitis C Treatments in Patients Infected With Both HIV and Hepatitis C Virus (HCV)#905855ClinicalTrials.gov
• Evaluation of the Efficacy and Safety Between Two Antiretroviral Regimens, in HIV-1-infected Treatment-naïve Subjects With Low CD4 Counts#860046ClinicalTrials.gov
• 1:1 Comparison of the Pocket Colposcope in Kenya#895131ClinicalTrials.gov
• Effect of COVID-19 pandemic on ART access and timely initiation in people living with HIV in 31 countries: a regression discontinuity design study#15503HAL (France)
• Long-Acting Antiretroviral Therapy for Breastfeeding Women With HIV Experiencing Barriers to Adherence in Zimbabwe: Modeling Clinical Impact and Cost-effectiveness#161320HAL (France)
• Ritonavir-Boosted GS-9137 vs. Ritonavir-Boosted Protease Inhibitor(s) in Combination With Background ART.#831707ClinicalTrials.gov
• The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age#844994ClinicalTrials.gov
• Rôle de la protéine autophagique LC3B au cours de l'étape d'entrée du VIH-1 dans les lymphocytes T CD4+#226784HAL (France)
• Comprehensive analysis of neutrophil immunomodulatory properties and FcR dynamics in HIV-1 infection and therapy#213126HAL (France)
• HIV-1 infection does not confer intrinsic resistance to cell death induced by cytotoxic T lymphocytes#238018bioRxiv / medRxiv
• HIV-1 virions selectively package circESYT2 to sculpt an actin scaffold that constraints egress#273203Europe PMC
• Maturation of HIV-1 neutralizing antibodies in a germinal center conditional expression mouse model.#323047NCBI PubMed Central
• Implementing Long-Acting Novel Antiretrovirals#845646ClinicalTrials.gov
• A Phase Ⅱa Clinical Study of CL-197 Capsules#886224ClinicalTrials.gov
• Real-world outcomes of immune checkpoint inhibitors in people with HIV and skin cancer: a multicentre study#294704HAL (France)
• Different Trends of Immune Activation Markers When Switching to Either Oral or Injectable Dual Antiretroviral Therapy Based on Integrase Inhibitors in People Living with HIV#370796HAL (France)
• Nevirapine vs Ritonavir-boosted Lopinavir in ART Naive HIV-infected Adults in a Resource Limited Setting#811551ClinicalTrials.gov
• Evaluating HITSystem 2.1 to Improve Viral Suppression in Kenya#849535ClinicalTrials.gov
• Observational Study Of A Protease Inhibitor (PI) Containing Regimen In Subjects With PI Mutations Selected During Prior Treatment With GW433908 (Fosamprenavir)#881310ClinicalTrials.gov
• Evaluation of Switch to Dolutegravir/Lamivudine (DTG/3TC) From Current Suppressive Antiretroviral Therapy in People Living With HIV (PLWH) Receiving Opioid Agonist Therapy (OAT)#909345ClinicalTrials.gov
• Ph1 Study of FT538 Alone and With Vorinostat for Persistent Low-Level HIV Viremia#981833ClinicalTrials.gov